STAT+: Compass says depression drug has long-lasting benefits

URL has been copied successfully!

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Plenty of news today, and also a deal that is running out soon: Buy one year of STAT+, get one year free.

Vertex makes its largest-ever deal 

Vertex said yesterday it will spend $10 billion to acquire Crinetics Pharmaceuticals, a biotech developing drugs for rare endocrine disorders.

Continue to STAT+ to read the full story…

Please follow us:
Follow by Email
X (Twitter)
Whatsapp
LinkedIn
Copy link

This post was originally published here